Taysha Gene Therapies (TSHA) Depreciation & Amortization (CF) (2020 - 2026)
Taysha Gene Therapies (TSHA) reported Depreciation & Amortization (CF) of $300000.0 for Q1 2026, little changed on a YoY basis from $300000.0 in Q1 2025, and little changed sequentially from $300000.0 in Q4 2025.
Taysha Gene Therapies (TSHA) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Taysha Gene Therapies (TSHA) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $300000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) changed 0.0% year-over-year to $300000.0; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (down 8.64% YoY), and the FY2025 full-year result was $1.1 million, down 11.65% from the prior year.
- Depreciation & Amortization (CF) was little changed at $300000.0 in Q1 2026, from $300000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $400000.0 in Q2 2023 to a low of $200000.0 in Q3 2025.
- A 5-year average of $309235.3 and a median of $300000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) jumped 712.5% in 2022 and slumped 33.33% in 2025, its largest moves.
- Tracing TSHA's Depreciation & Amortization (CF) over 5 years: stood at $362000.0 in 2022, then increased by 10.5% to $400000.0 in 2023, then retreated by 24.0% to $304000.0 in 2024, then fell by 1.32% to $300000.0 in 2025, then changed by 0.0% to $300000.0 in 2026.
- Business Quant data shows TSHA's Depreciation & Amortization (CF) at $300000.0 in Q1 2026, $300000.0 in Q4 2025, and $200000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Taysha Gene Therapies | 2.14 Bn | 2.14 Bn | - | 300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 300,000.00 |
| Dec 31, 2025 | 300,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | 304,000.00 |
| Dec 31, 2024 | 304,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 300,000.00 |
| Mar 31, 2024 | 300,000.00 |
| Dec 31, 2023 | 400,000.00 |
| Dec 31, 2023 | 400,000.00 |